EACH VIAL CONTAINS 2MG OF CJC 1295
Supplied for Research Purposes Only
This information and product is provided for research purposes only. We do not provide any advice on the usage of these products as UK Law prevents this. Customers should check the legality of this product in their own country prior to purchase.
Benefits and uses:
Increased protein synthesis contributes to increased lean body mass.
Amplification of the Growth of Muscle
Densification of the bone tissue
Enhanced Capabilities of the Immune System
Enhanced Capabilities of Thinking and Remembering
Increased Quantities of Collagen Produced
A greater reduction in body fat
Enhanced Capacity for the Repair and Regeneration of Cells
CJC-1295 encourages slow-wave deep sleep, which is responsible for the maximum level of both muscle growth and memory retention and rejuvenation.
150 mcg twice daily
What is CJC-1295?
The compound known as CJC-1295 is a synthetic analogue of the hormone known as GHRH, which stands for growth hormone releasing hormone. It has been discovered to be highly effective in increasing the secretion of growth hormone and IGF-1, without having a detrimental effect on the pulsatility of GH secretion.
Because of its increased specificity as a GHRH, CJC-1295 is frequently coupled with ipamorelin in clinical trials. Increases in growth hormone secretion are produced by this peptide, just like those produced by other peptides in its family; however, this peptide does not cause an increase in hunger, nor does it cause an increase in cortisol, acetylcholine, prolactin, or aldosterone. When coupled with ipamorelin, it has been discovered that this particular peptide is extremely well tolerated and produces optimal results.
HOW CJC-1295 ACTS IN THE BODY
CJC 1295 has several positive effects on the body, including the following:
Growth hormone secretion and IGF-1 levels have both increased, but there has been no accompanying rise in prolactin.
CJC 1295: GHRH & DAC
The hypothalamus is responsible for the production of GHRH, also known as growth hormone releasing hormone. This causes a pulsatile release of growth hormone (GH) from the pituitary gland, which is caused by its pulsatile release from the hypothalamus. The half-life of GHRH is only a few minutes, which is quite a short amount of time. Half-life is defined as the amount of time needed to remove half of the drug from the blood. The shorter the half-life, the more quickly the chemical is eliminated from the body, which in turn results in the substance having less of an impact on the body.
The active section of GHRH consists of the first 29 amino acids in the protein. They are offered for sale as a synthetic peptide that goes by the name Sermorelin. Additional modifications were made to sermorelin in order to shorten its half-life to thirty minutes. This is referred to as the CJC 1295. The CJC-1295 formula underwent additional modification when the DAC (Drug Affinity Complex) was incorporated into it. Because DAC binds to albumin, which is a blood protein, the half-life of the compound is extended to eight days. It is known by the name CJC 1295 + DAC. CJC 1295 can also be compounded into a non-DAC form, which simulates a more natural physiologic GH surge each night.
Because the DAC only binds to albumin for a longer period of time, patients only need to receive injections once or twice per week rather than daily. However, because to the extended half-life and generally constant blood level, the GHRH receptor is subjected to an unnaturally continual stimulus for the release of GH from the pituitary gland. This is not physiological. This may result in a decrease in the GH pulse amplitude, which in turn will lead to a reduction in the activation of GH tissue.
Using CJC 1295 Without Risk
If you are taking a long-acting CJC molecule, it is recommended that you take a "hormone holiday" of three months every three to six months in order to give your pituitary gland time to "recover." During the holiday season, the combination of CJC 1295 and DAC is replaced by sermorelin.
The so-called "hormone holidays" may also help reduce the possibility of acquiring GH resistance. This resistance, also known as insensitivity, could be the result of the formation of antibodies that bind to and inactivate GH, or it could be the result of a decrease in the number of GH receptors present on tissues (down-regulation). These are purely theoretical concerns at this point because no extensive research over extended periods of time have been conducted to shed light on the issues.
Injection site reactions (such as irritation, erythema, induration, discomfort, and itching), headache, diarrhoea, vasodilation (such as flushing, warmth, and transitory hypotension), nausea, and abdominal pain are all potential adverse events to CJC-1295.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. Epub 2005 Dec 13.
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009 Dec;19(6):471-7. doi: 10.1016/j.ghir.2009.03.001. Epub 2009 Apr 21.
Merriam GR1, Buchner DM, Prinz PN, Schwartz RS, Vitiello MV. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine. 1997 Aug;7(1):49-52.
Sanders JL, Guo W, O'Meara ES, Kaplan RC, Pollak MN, Bartz TM, Newman AB, Fried LP, Cappola AR. Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):953-959
Li Z1, Li Y2. Effect of growth hormone releasing hormone on chondrocytes of osteoarthritis. Korean J Intern Med. 2019 Dec 26. doi: 10.3904/kjim.2018.399.
Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle. 2010 Oct 15;9(20):4110-6. Epub 2010 Oct 27.
Martínez-Moreno CG, Calderón-Vallejo D, Harvey S, Arámburo C, Quintanar JL. Growth Hormone (GH) and Gonadotropin-Releasing Hormone (GnRH) in the Central Nervous System: A Potential Neurological Combinatory Therapy? Int J Mol Sci. 2018 Jan 26;19(2). pii: E375. doi: 10.3390/ijms19020375.
Bianchi VE, Locatelli V, Rizzi L. Neurotrophic and Neuroregenerative Effects of GH/IGF1. Int J Mol Sci. 2017 Nov 17;18(11). pii: E2441. doi: 10.3390/ijms18112441.
Sanchez-Bezanilla S, Åberg ND, Crock P, Walker FR, Nilsson M, Isgaard J, Ong LK. Growth Hormone Promotes Motor Function after Experimental Stroke and Enhances Recovery-Promoting Mechanisms within the Peri-Infarct Area. Int J Mol Sci. 2020 Jan 17;21(2). pii: E606. doi: 10.3390/ijms21020606.
Yuan T1, Ying J, Jin L, Li C, Gui S, Li Z, Wang R, Zuo Z, Zhang Y. The role of serum growth hormone and insulin-like growth factor-1 in adult humans brain morphology. Aging (Albany NY). 2020 Jan 22;12(2):1377-1396. doi: 10.18632/aging.102688. Epub 2020 Jan 22.